These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32645019)

  • 1. Importance of medicine quality in achieving universal health coverage.
    Ozawa S; Higgins CR; Yemeke TT; Nwokike JI; Evans L; Hajjou M; Pribluda VS
    PLoS One; 2020; 15(7):e0232966. PubMed ID: 32645019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo.
    Ozawa S; Haynie DG; Bessias S; Laing SK; Ngamasana EL; Yemeke TT; Evans DR
    Am J Trop Med Hyg; 2019 May; 100(5):1149-1157. PubMed ID: 30675851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model.
    Jackson KD; Higgins CR; Laing SK; Mwila C; Kobayashi T; Ippolito MM; Sylvia S; Ozawa S
    BMC Public Health; 2020 Jul; 20(1):1083. PubMed ID: 32646393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor-quality antimalarials further health inequities in Uganda.
    Evans DR; Higgins CR; Laing SK; Awor P; Ozawa S
    Health Policy Plan; 2019 Dec; 34(Supplement_3):iii36-iii47. PubMed ID: 31816072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tackling the blind spot of poor-quality medicines in Universal Health Coverage.
    Orubu ESF; Ching C; Zaman MH; Wirtz VJ
    J Pharm Policy Pract; 2020; 13():40. PubMed ID: 32670594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study.
    Ozawa S; Evans DR; Higgins CR; Laing SK; Awor P
    Malar J; 2019 Jan; 18(1):5. PubMed ID: 30626380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The economic impact of substandard and falsified antimalarial medications in Nigeria.
    Beargie SM; Higgins CR; Evans DR; Laing SK; Erim D; Ozawa S
    PLoS One; 2019; 14(8):e0217910. PubMed ID: 31415560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pathway to Achieving Universal Health Coverage in the Democratic Republic of Congo: Obstacles and Prospects.
    Issa M
    Cureus; 2023 Jul; 15(7):e41935. PubMed ID: 37583749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
    Petersen A; Held N; Heide L;
    PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
    GBD 2019 Universal Health Coverage Collaborators
    Lancet; 2020 Oct; 396(10258):1250-1284. PubMed ID: 32861314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
    Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
    JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Legislating for universal access to medicines: a rights-based cross-national comparison of UHC laws in 16 countries.
    Perehudoff SK; Alexandrov NV; Hogerzeil HV
    Health Policy Plan; 2019 Dec; 34(Supplement_3):iii48-iii57. PubMed ID: 31816073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in maintaining medicine quality while aiming for universal health coverage: a qualitative analysis from Indonesia.
    Hasnida A; Kok MO; Pisani E
    BMJ Glob Health; 2021 May; 6(Suppl 3):. PubMed ID: 34049935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substandard and Falsified Antibiotics and Medicines against Noncommunicable Diseases in Western Cameroon and Northeastern Democratic Republic of Congo.
    Schäfermann S; Hauk C; Wemakor E; Neci R; Mutombo G; Ngah Ndze E; Cletus T; Nyaah F; Pattinora M; Wistuba D; Helmle I; Häfele-Abah C; Gross H; Heide L
    Am J Trop Med Hyg; 2020 Aug; 103(2):894-908. PubMed ID: 32394884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.
    GBD 2019 Human Resources for Health Collaborators
    Lancet; 2022 Jun; 399(10341):2129-2154. PubMed ID: 35617980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are we doing enough to prevent poor-quality antimalarial medicines in the developing world?
    Walker EJ; Peterson GM; Grech J; Paragalli E; Thomas J
    BMC Public Health; 2018 May; 18(1):630. PubMed ID: 29764407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.
    Garcia MM; Azevedo PS; Mirelman A; Safatle LP; Iunes R; Bennie MC; Godman B; Guerra Junior AA
    Front Pharmacol; 2020; 11():370. PubMed ID: 32351382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of antiretroviral, antimalarial and antituberculosis medicines in Zambia: Findings of routine post-marketing surveillance.
    Jere E; Munkombwe D; Mukosha M; Mudenda S; Kalungia AC; Chabalenge B
    J Med Access; 2024; 8():27550834241266755. PubMed ID: 39071988
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.